Please use this identifier to cite or link to this item:
Type: Artigo
Title: Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes
Author: Prada, P.O.
Saad, M.J.A.
Abstract: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. Areas covered: It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. Expert opinion: A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease
Subject: Hipoglicemiantes
Resistência à insulina
Diabetes mellitus tipo 2
Country: Reino Unido
Editor: Taylor & Francis
Citation: Expert Opinion On Investigational Drugs. , v. 22, n. 6, p. 751 - 763, 2013.
Rights: fechado
Identifier DOI: 10.1517/13543784.2013.802768
Date Issue: 2013
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
2-s2.0-84878214369.pdf6.04 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.